Longevity & AgingAsthma Is Not One Disease and Precision Medicine Is Finally Catching Up
Asthma is no longer treated as a single disease. This review describes how patients differ in visible traits (phenotypes), underlying biology (endotypes) and treatment response (theratypes). Type 2-high asthma, driven by IL-4, IL-5 and IL-13, is well characterized and has targeted biologics. Type 2-low asthma, often neutrophilic and steroid-resistant, is poorly understood. Point-of-care biomarkers such as blood eosinophils, FeNO and IgE help stratify patients but overlap considerably and can mislead when used alone. The authors argue that multi-omics, advanced lung imaging, single-cell and spatial transcriptomics, and machine learning can define endotypes more precisely. They also introduce the new EAACI hypersensitivity nomenclature, including types V, VI and VII asthma, to support stratified management.